Good clinical research practice (GCRP) in pharmacodynamic studies of neuromuscular blocking agents III : The 2023 Geneva revision
© 2023 The Authors. Acta Anaesthesiologica Scandinavica published by John Wiley & Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation..
The set of guidelines for good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents was developed following an international consensus conference in Copenhagen in 1996 (Viby-Mogensen et al., Acta Anaesthesiol Scand 1996, 40, 59-74); the guidelines were later revised and updated following the second consensus conference in Stockholm in 2005 (Fuchs-Buder et al., Acta Anaesthesiol Scand 2007, 51, 789-808). In view of new devices and further development of monitoring technologies that emerged since then, (e.g., electromyography, three-dimensional acceleromyography, kinemyography) as well as novel compounds (e.g., sugammadex) a review and update of these recommendations became necessary. The intent of these revised guidelines is to continue to help clinical researchers to conduct high-quality work and advance the field by enhancing the standards, consistency, and comparability of clinical studies. There is growing awareness of the importance of consensus-based reporting standards in clinical trials and observational studies. Such global initiatives are necessary in order to minimize heterogeneous and inadequate data reporting and to improve clarity and comparability between different studies and study cohorts. Variations in definitions of endpoints or outcome variables can introduce confusion and difficulties in interpretation of data, but more importantly, it may preclude building of an adequate body of evidence to achieve reliable conclusions and recommendations. Clinical research in neuromuscular pharmacology and physiology is no exception.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:67 |
|---|---|
| Enthalten in: |
Acta anaesthesiologica Scandinavica - 67(2023), 8 vom: 22. Sept., Seite 994-1017 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fuchs-Buder, Thomas [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.08.2023 Date Revised 21.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/aas.14279 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358473055 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358473055 | ||
| 003 | DE-627 | ||
| 005 | 20231226074820.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/aas.14279 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1194.xml |
| 035 | |a (DE-627)NLM358473055 | ||
| 035 | |a (NLM)37345870 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fuchs-Buder, Thomas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Good clinical research practice (GCRP) in pharmacodynamic studies of neuromuscular blocking agents III |b The 2023 Geneva revision |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.08.2023 | ||
| 500 | |a Date Revised 21.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Acta Anaesthesiologica Scandinavica published by John Wiley & Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation. | ||
| 520 | |a The set of guidelines for good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents was developed following an international consensus conference in Copenhagen in 1996 (Viby-Mogensen et al., Acta Anaesthesiol Scand 1996, 40, 59-74); the guidelines were later revised and updated following the second consensus conference in Stockholm in 2005 (Fuchs-Buder et al., Acta Anaesthesiol Scand 2007, 51, 789-808). In view of new devices and further development of monitoring technologies that emerged since then, (e.g., electromyography, three-dimensional acceleromyography, kinemyography) as well as novel compounds (e.g., sugammadex) a review and update of these recommendations became necessary. The intent of these revised guidelines is to continue to help clinical researchers to conduct high-quality work and advance the field by enhancing the standards, consistency, and comparability of clinical studies. There is growing awareness of the importance of consensus-based reporting standards in clinical trials and observational studies. Such global initiatives are necessary in order to minimize heterogeneous and inadequate data reporting and to improve clarity and comparability between different studies and study cohorts. Variations in definitions of endpoints or outcome variables can introduce confusion and difficulties in interpretation of data, but more importantly, it may preclude building of an adequate body of evidence to achieve reliable conclusions and recommendations. Clinical research in neuromuscular pharmacology and physiology is no exception | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a depth of neuromuscular blockade | |
| 650 | 4 | |a neuromuscular monitoring | |
| 650 | 4 | |a neuromuscular research | |
| 650 | 4 | |a pharmacodynamics | |
| 650 | 4 | |a postoperative pulmonary complications | |
| 650 | 4 | |a time course of neuromuscular blockade | |
| 650 | 7 | |a Neuromuscular Blocking Agents |2 NLM | |
| 650 | 7 | |a Sugammadex |2 NLM | |
| 650 | 7 | |a 361LPM2T56 |2 NLM | |
| 700 | 1 | |a Brull, Sorin J |e verfasserin |4 aut | |
| 700 | 1 | |a Fagerlund, Malin Jonsson |e verfasserin |4 aut | |
| 700 | 1 | |a Renew, J Ross |e verfasserin |4 aut | |
| 700 | 1 | |a Cammu, Guy |e verfasserin |4 aut | |
| 700 | 1 | |a Murphy, Glenn S |e verfasserin |4 aut | |
| 700 | 1 | |a Warlé, Michiel |e verfasserin |4 aut | |
| 700 | 1 | |a Vested, Matias |e verfasserin |4 aut | |
| 700 | 1 | |a Fülesdi, Béla |e verfasserin |4 aut | |
| 700 | 1 | |a Nemes, Reka |e verfasserin |4 aut | |
| 700 | 1 | |a Columb, Malachy O |e verfasserin |4 aut | |
| 700 | 1 | |a Damian, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Davis, Peter J |e verfasserin |4 aut | |
| 700 | 1 | |a Iwasaki, Hajime |e verfasserin |4 aut | |
| 700 | 1 | |a Eriksson, Lars I |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta anaesthesiologica Scandinavica |d 1957 |g 67(2023), 8 vom: 22. Sept., Seite 994-1017 |w (DE-627)NLM000055956 |x 1399-6576 |7 nnns |
| 773 | 1 | 8 | |g volume:67 |g year:2023 |g number:8 |g day:22 |g month:09 |g pages:994-1017 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/aas.14279 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 67 |j 2023 |e 8 |b 22 |c 09 |h 994-1017 | ||